[{"address1": "270 Longwood Road South", "city": "Hamilton", "state": "ON", "zip": "L8P 0A6", "country": "Canada", "phone": "289 799 0891", "website": "https://fusionpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.", "fullTimeEmployees": 101, "companyOfficers": [{"maxAge": 1, "name": "Dr. John F. Valliant Ph.D.", "age": 52, "title": "Founder, CEO & Director", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 864717, "exercisedValue": 0, "unexercisedValue": 2176405}, {"maxAge": 1, "name": "Mr. John J. Crowley CPA", "age": 49, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": 670104, "exercisedValue": 0, "unexercisedValue": 292790}, {"maxAge": 1, "name": "Dr. Eric  Burak Ph.D.", "age": 58, "title": "Chief Technology Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 638040, "exercisedValue": 0, "unexercisedValue": 570916}, {"maxAge": 1, "name": "Mr. Mohit  Rawat", "age": 43, "title": "President & Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher Paul Leamon Ph.D.", "age": 57, "title": "Chief Scientific Officer", "yearBorn": 1966, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amanda  Cray", "title": "Senior Director of Investor Relations & Corporate Communications", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria D. Stahl", "age": 52, "title": "Chief Legal Officer", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric S. Hoffman Ph.D.", "age": 53, "title": "Senior Vice President of Business Development", "yearBorn": 1970, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Cara  Ferreira Ph.D.", "title": "Chief of Staff", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joanne  Schindler", "title": "Executive Vice President of Medical Director & Clinical Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.89, "open": 11.09, "dayLow": 10.8, "dayHigh": 11.56, "regularMarketPreviousClose": 10.89, "regularMarketOpen": 11.09, "regularMarketDayLow": 10.8, "regularMarketDayHigh": 11.56, "beta": -0.871, "forwardPE": -8.39416, "volume": 1103670, "regularMarketVolume": 1103670, "averageVolume": 834365, "averageVolume10days": 1124790, "averageDailyVolume10Day": 1124790, "bidSize": 1100, "askSize": 800, "marketCap": 832666688, "fiftyTwoWeekLow": 2.31, "fiftyTwoWeekHigh": 11.56, "priceToSalesTrailing12Months": 377.11353, "fiftyDayAverage": 6.9715, "twoHundredDayAverage": 4.6006, "currency": "USD", "enterpriseValue": 693947136, "floatShares": 43208909, "sharesOutstanding": 72405800, "sharesShort": 3201042, "sharesShortPriorMonth": 89602, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.0442, "heldPercentInsiders": 0.05153, "heldPercentInstitutions": 0.84159, "shortRatio": 2.13, "shortPercentOfFloat": 0.0473, "impliedSharesOutstanding": 72405800, "bookValue": 2.942, "priceToBook": 3.9089055, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -91335000, "trailingEps": -1.61, "forwardEps": -1.37, "enterpriseToRevenue": 314.288, "enterpriseToEbitda": -7.371, "52WeekChange": 2.5940595, "SandP52WeekChange": 0.20883334, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "FUSN", "underlyingSymbol": "FUSN", "shortName": "Fusion Pharmaceuticals Inc.", "longName": "Fusion Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1593178200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d9536ffd-ba4c-326e-b439-759f4bfcfe15", "messageBoardId": "finmb_421477092", "gmtOffSetMilliseconds": -18000000, "currentPrice": 11.5, "targetHighPrice": 20.0, "targetLowPrice": 9.0, "targetMeanPrice": 13.33, "targetMedianPrice": 12.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 191348000, "totalCashPerShare": 2.643, "ebitda": -94142000, "totalDebt": 52628000, "quickRatio": 11.083, "currentRatio": 11.63, "totalRevenue": 2208000, "debtToEquity": 27.924, "revenuePerShare": 0.038, "returnOnAssets": -0.24238001, "returnOnEquity": -0.49155998, "freeCashflow": -55110500, "operatingCashflow": -83222000, "revenueGrowth": 11.084, "operatingMargins": -9.6655, "financialCurrency": "USD", "trailingPegRatio": null}]